此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

治疗与 RPGR 基因变异相关的 X 连锁视网膜色素变性的基因治疗试验

2026年9月23日 更新者:MeiraGTx Ocular UK Ltd

AAV5-RPGR 治疗与 RPGR 基因变异相关的 X 连锁视网膜色素变性的第 3 期随机对照研究

A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

研究概览

研究类型

介入性

注册 (实际的)

105

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Glostrup Municipality、丹麦、2600
        • Rigshospitalet Glostrup
      • Jerusalem、以色列、91120
        • Hadassah Medical Center
    • Ontario
      • Toronto、Ontario、加拿大、M5G 1X8
        • Hospital For Sick Children
      • Florence、意大利、50134
        • Azienda Ospedaliero Universitaria Careggi
      • Milan、意大利、20142
        • Ospedale San Paolo
      • Naples、意大利、80131
        • Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli
      • Roma、意大利、00198
        • IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS
      • Ghent、比利时、9000
        • UZ Gent
      • Paris、法国、75012
        • Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
      • Basel、瑞士、4031
        • University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical
      • Lausanne、瑞士、1004
        • Universite de Lausanne, Hopital ophtalmique Jules-Gonin
    • California
      • La Jolla、California、美国、92093 0946
        • Shiley Eye Institute Jacobs Retina Center
      • Los Angeles、California、美国、90027
        • Childrens Hospital
      • Palo Alto、California、美国、94303
        • Stanford Health Care
    • Florida
      • Gainesville、Florida、美国、32607
        • VitreoRetinal Associates, PA
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital - Center for Celiac Research and Treatment
    • Michigan
      • Ann Arbor、Michigan、美国、48105
        • Univ of Michigan Medical Center
    • North Carolina
      • Durham、North Carolina、美国、27705
        • Duke Eye Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburgh Medical Center (UPMC)
    • Texas
      • Bellaire、Texas、美国、77401
        • Retina Consultants of Houston
      • Edinburgh、英国、EH3 9HA
        • NHS Lothian
      • Glasgow、英国、G12 0YN
        • Gartnavel General Hospital
      • Leeds、英国、LS9 7TF
        • St James University Hospital
      • London、英国、EC1V 2PD
        • Moorfields Eye Hospital
      • Amsterdam、荷兰、1105AZ
        • VUMC Amsterdam
      • Nijmegen、荷兰、6525EX
        • Radboudumc
      • Madrid、西班牙、28040
        • Hosp Univ Fund Jimenez Diaz

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

3年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female
  • 3 years of age or older
  • Has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory

Exclusion Criteria:

  • Has had ocular surgery within 3 months prior to screening or is anticipated to require ocular surgery within 6 months after the study intervention administration
  • Any investigational ocular treatment or any other ocular treatment that could confound the interpretation of the efficacy results or affect participant compliance with the visit schedule
  • Has undergone prior retinal surgery involving the macula, macular laser photocoagulation, external-beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental - Immediate Treatment

Intermediate dose.

Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group

其他名称:
  • 斯帕罗沃韦克

No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)

其他:Deferred Treatment

Deferred Treatment

Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group

其他名称:
  • 斯帕罗沃韦克

No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)

实验性的:Experimental Immediate Treatment

Low dose.

Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group

其他名称:
  • 斯帕罗沃韦克

No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline to Week 52 in Vision-guided Mobility Assessment (VMA) as Measured by the Ability of the Participant to Navigate Through a VMA Maze
大体时间:From Baseline to 52 Weeks

Change from baseline to Week 52 in VMA as measured by the ability of the participant to navigate through a VMA maze.

From Baseline to 52 Weeks

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in Mean Retinal Sensitivity Within the Central 10 Degrees Excluding Scotoma (Mean Retinal Sensitivity Within the Central 10 Degree Excluding Scotoma in Static Perimetry [MRS10]) in Static Perimetry at Week 52
大体时间:From Baseline to Week 52

Change from baseline in mean retinal sensitivity within the central 10 degrees excluding scotoma (MRS10) in static perimetry at Week 52 will be assessed.

From Baseline to Week 52
Change From Baseline in Mean Retinal Sensitivity of Worse-seeing Eye Within the Central 10 Degrees Excluding Scotoma in Static Perimetry (MRS10) at Week 52
大体时间:From Baseline to Week 52

Change from baseline in mean retinal sensitivity of worse-seeing eye within the central 10 degrees excluding scotoma in static perimetry (MRS10) at Week 52 will be assessed.

From Baseline to Week 52
Change in Retinal Function as Assessed by Pointwise Response in Full Visual Field at Week 52
大体时间:From Baseline to Week 52

Pointwise response in full visual field at Week 52 will be assessed.

From Baseline to Week 52
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in Full Visual Field at Week 52
大体时间:From Baseline to Week 52

Pointwise response in worse-seeing eye in full visual field at Week 52 will be assessed.

From Baseline to Week 52
Change in Retinal Function as Assessed by Pointwise Response in the Central 30 Degrees Visual Field at Week 52
大体时间:From Baseline to Week 52

Pointwise response in the central 30 degrees visual field at Week 52 will be assessed.

From Baseline to Week 52
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in the Central 30 Degrees Visual Field at Week 52
大体时间:From Baseline to Week 52

Pointwise response in worse-seeing eye in the central 30 degrees visual field at Week 52 will be assessed.

From Baseline to Week 52
Change From Baseline in Retinal Function as Assessed by Mean Retinal Sensitivity Within the Full Visual Field (MRS90) in Static Perimetry at Week 52
大体时间:From Baseline to Week 52

Change from baseline in retinal function as assessed by mean retinal sensitivity within the full visual field (MRS90) in static perimetry at Week 52 will be assessed.

From Baseline to Week 52
Change in Functional Vision by Using Vision-guided Mobility Assessment (VMA) Response in the "Worse-seeing Eye" at Week 52
大体时间:From Baseline to Week 52

Change in functional vision by using VMA assessment in the "Worse-seeing Eye" at Week 52.

From Baseline to Week 52
Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52
大体时间:From Baseline to Week 52

Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52.

From Baseline to Week 52
Change From Baseline in Visual Function as Assessed by Monocular Low Luminance Visual Acuity Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter score at Week 52
大体时间:From Baseline to Week 52

Change from baseline in visual function as assessed by monocular low luminance visual acuity using the ETDRS chart letter score at Week 52.

From Baseline to Week 52
Change From Baseline in Visual Function as Assessed by monocular Best Corrected Visual Acuity (BCVA) Using the ETDRS Chart Letter Score at Week 52
大体时间:From Baseline to Week 52

Change From Baseline in visual function as assessed by monocular BCVA using the ETDRS chart letter score at Week 52.

From Baseline to Week 52
Change From Baseline in Visual Function as Assessed by Low Luminance Visual Acuity Using the ETDRS Chart Letter Score in Worse-seeing Eye at Week 52
大体时间:From Baseline to Week 52

Change from baseline in visual function as assessed by low luminance visual acuity using the ETDRS chart letter score in worse-seeing eye at Week 52.

From Baseline to Week 52
Number of Participants with Ocular and Non-ocular Adverse Events
大体时间:Day 1 - Week 52

Number of participants with ocular and non-ocular adverse events will be assessed.

Day 1 - Week 52
Number of Participants With Abnormalities in Laboratory Assessments
大体时间:Day 1 - 52 Weeks

Number of participants with abnormalities in laboratory assessments will be assessed.

Day 1 - 52 Weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Study Director、MeiraGTx Ocular UK Ltd

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年12月4日

初级完成 (实际的)

2024年9月30日

研究完成 (实际的)

2024年9月30日

研究注册日期

首次提交

2020年11月5日

首先提交符合 QC 标准的

2020年12月15日

首次发布 (实际的)

2020年12月17日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • CR109258
  • 2020-002873-88 (EudraCT编号)
  • MGT-RPGR-021 (其他标识符:MeiraGTx Ocular UK Ltd)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅